Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches B细胞恶性肿瘤经CAR-T细胞治疗后复发：挑战与未来 1 2 3 4 equal first-author 1 2 3 4 equal 1 2 3 4 corresp corresp Yongxian HU, 1313016@zju.edu.cn Yongxian HU, 1313016@zju.edu.cn He HUANG, huanghe@zju.edu.cn He HUANG, huanghe@zju.edu.cn huanghe@zju.edu.cn https://orcid.org/0000-0002-2723-1621 1 2 3 4 corresp Yongxian HU, 1313016@zju.edu.cn Yongxian HU, 1313016@zju.edu.cn 1313016@zju.edu.cn https://orcid.org/0000-0001-9564-1852 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China 浙江大学医学院附属第一医院骨髓移植中心，中国杭州市，310003 浙江大学医学院附属第一医院骨髓移植中心，中国杭州市，310003 Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China 浙江大学医学中心良渚实验室，中国杭州市，311121 浙江大学医学中心良渚实验室，中国杭州市，311121 Institute of Hematology, Zhejiang University, Hangzhou 310058, China Institute of Hematology, Zhejiang University, Hangzhou 310058, China 浙江大学血液学研究所，中国杭州市，310058 浙江大学血液学研究所，中国杭州市，310058 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310058, China Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310058, China 干细胞与细胞免疫治疗浙江省工程研究中心，中国杭州市，310058 干细胞与细胞免疫治疗浙江省工程研究中心，中国杭州市，310058 Chimeric antigen receptor-T (CAR-T) cell therapy, as a novel cellular immunotherapy, has dramatically reshaped the landscape of cancer treatment, especially in hematological malignancies. However, relapse is still one of the most troublesome obstacles to achieving broad clinical application. The intrinsic factors and superior adaptability of tumor cells mark a fundamental aspect of relapse. The unique biological function of CAR-T cells governed by their special CAR construction also affects treatment efficacy. Moreover, complex cross-interactions among CAR-T cells, tumor cells, and the tumor microenvironment (TME) profoundly influence clinical outcomes concerning CAR-T cell function and persistence. Therefore, in this review, based on the most recent discoveries, we focus on the challenges of relapse after CAR-T cell therapy in B-cell malignancies from the perspective of tumor cells, CAR-T cells, and the TME. We also discuss the corresponding basic and clinical approaches that may overcome the problem in the future. We aim to provide a comprehensive understanding for scientists and physicians that will help improve research and clinical practice. 嵌合抗原受体T(CAR-T)细胞疗法作为一种新型的细胞免疫疗法，极大地改变了癌症治疗的格局，尤其是在血液系统恶性肿瘤中。然而，CAR-T细胞治疗后复发仍然是影响其广泛应用于临床的主要障碍之一。肿瘤细胞内在特性和较强的适应能力，是复发的一个重要原因。由于特殊CAR结构的存在，CAR-T细胞具有的独特生物学功能同样影响治疗效果。此外，肿瘤微环境中错综复杂的相互作用深刻影响CAR-T细胞功能及临床预后。因此，本综述基于最新发现，从肿瘤细胞、CAR-T细胞和肿瘤微环境角度，关注B细胞恶性肿瘤经CAR-T细胞治疗后复发，讨论未来相应的基础和临床策略，以提供全面的认识，有助于提高研究和临床应用。 Chimeric antigen receptor-T (CAR-T) B-cell malignancies Mechanisms of relapse Strategy 嵌合抗原受体T（CAR-T） B细胞恶性肿瘤 复发机制 策略 1 Introduction 1 In recent decades, cancer treatment strategies have progressed through surgical resection, radiotherapy, chemotherapy, and targeted therapy, each of which has marked a milestone in treatment history. Chimeric antigen receptor-T (CAR-T) cell therapy, the adoptive transfer of T cells redirected to target tumor cells, has achieved remarkable outcomes in the treatment of B-cell malignancies. For the first time, complete remission (CR) has been achieved and maintained in a girl with B-cell acute lymphoblastic leukemia (B-ALL) who received cluster of differentiation 19 (CD19) CAR-T cell therapy a decade ago ( Grupp et al., 2013 Grupp et al., 2013 ). Based on their outstanding clinical efficacy, a total of six CAR-T cell-based products have been approved for the treatment of B-cell malignancies, including tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), with an overall CR rate of 80%‍–‍90% in relapsed/refractory (R/R) B-ALL patients and 50% in R/R B-cell lymphoma patients ( Larson and Maus, 2021 Larson and Maus, 2021 ). Ever-increasing clinical trials are being conducted and optimized treatment strategies measured. Nevertheless, relapse remains the major obstacle to be addressed ( Miao et al., 2021 Miao et al., 2021 ). Clinical evidence indicates that a large proportion of patients with B-cell malignancies suffer from relapse after CAR-T cell therapy, which brings even greater efforts to achieve remission again. Recent discoveries have uncovered mysterious mechanisms underlying relapse after CAR-T cell therapy. Tumor cells, CAR-T cells, and the tumor microenvironment (TME) integrally contribute to the course of relapse, with dismal outcomes. Relevant optimization and breakthroughs to promote antigen recognition, enhance CAR-T cell function, and develop combinational treatment strategies provide insights for better clinical efficacy. In this review, based on the most recent discoveries, we focus on the challenges of relapse after CAR-T cell therapy in B-cell malignancies by discussing the underlying mechanisms from the perspective of tumor cells, CAR-T cells, and the TME, and propose promising basic and clinical approaches that may overcome the obstacle in the future. 2 Clinical relevance 1 Although CD19 CAR-T cell therapy has achieved amazing overall CR rates in patients with R/R B-ALL and B-cell lymphoma ( Larson and Maus, 2021 Larson and Maus, 2021 ), 40%–60% of CR patients eventually experience relapse. At the 2021 American Society of Hematology (ASH) annual meeting, real-world outcomes of tisa-cel treatment of pediatric and young adult patients with R/R B-ALL showed that, after a median follow-up of 21.5 months (11.9‍–‍37.2 months), the median event-free survival (EFS) was 14.0 months (95% confidence interval (CI), 9.8‍–‍24.8) and the median relapse-free survival (RFS) was 23.9 months (13.0‍–‍not estimated (NE)). The 12-month EFS rate was 54.3% and the RFS rate was 62.3% ( John et al., 2021 John et al., 2021 ). In axi-cel-treated patients with R/R large B-cell lymphoma (LBCL), a 12-month EFS rate of 43% (95% CI, 33%‍–‍52%) and a 24-month EFS rate of 38% (95% CI, 28%‍–‍47%) were reported ( Jacobson et al., 2021 Jacobson et al., 2021 ). The relapse after CAR-T cell therapy in B-cell malignancies is defined as the recurrence of tumor cells after achieving CR by target-specific CAR-T cell infusion, such as CD19 CAR-T. Generally, the relapse can be categorized as the bone marrow relapse, the extramedullary relapse (such as in the central nervous system (CNS) or testis), or a combined relapse according to anatomical sites ( Tallen et al., 2010 Tallen et al., 2010 ). More specifically, the relapse can also be classified as antigen-positive or antigen-negative based on the expression profile of initially targeted antigens of tumor cells. The prognosis in each type of relapse is historically diverse. The pattern of relapse is influenced by various factors, including the nature of tumor cell itself, the properties of the CAR-T cells, and interaction with the specific TME ( Gaudichon et al., 2019 Gaudichon et al., 2019 ). 3 Challenges of relapse after CAR-T cell therapy in B-cell malignancies 1 Tumor cells, CAR-T cells, and the TME can each greatly affect the long-term clinical outcomes after CAR-T cell therapy ( Fig. 1 Fig. 1 ). 3.1 Tumor cell 2 The conceptualization of hallmarks of cancer depicts the complexity of tumor cells, and this also applies to B-cell malignancies ( Hanahan, 2022 Hanahan, 2022 ). Tumor cells with native heterogeneity and superior adaptability commonly resist eradication by CAR-T cells, leading to eventual relapse, as seen in both antigen-positive relapse and antigen-negative relapse ( Fig. 2 Fig. 2 ). 3.1.1　Heterogeneity 3 Tumor heterogeneity is widely recognized. The generation of intra-tumoral phenotypic diversity lays a foundation for the proliferative expansion and selective survival of the fittest tumor cell, which promotes clonal evolution and malignant progression ( Mcgranahan and Swanton, 2017 Mcgranahan and Swanton, 2017 ). The heterogeneity can be partly achieved by stochastic mutations in individual tumor cells that generate the most adaptative subclones in response to the alteration of the TME or specific cancer therapies. In addition, a selective differentiation hierarchy inherited from a cancer stem cell (CSC) with indefinite self-renewal ability also contributes to the distinct cell types ( Prasetyanti and Medema, 2017 Prasetyanti and Medema, 2017 ). The hierarchy can be plastic and be reversed by terminally differentiated cells acquiring a mutation and dedifferentiating into CSCs. Phenotypic heterogeneity is well reflected by the pattern of expression of antigens on tumor cells. Indeed, in B-cell malignancies, heterogenous antigen density of CD19, CD20, or CD22 has been be detected from the same patient-derived tumor cells ( Kailayangiri et al., 2020 Kailayangiri et al., 2020 ). Those tumor cells with low or negative antigen expression levels before CAR-T cell infusion may have a chance to escape and undergo secondary clonal expansion. Surprisingly, sequential loss of tumor surface antigens in lymphoma was reported even after multiple infusions of CAR-T cells with different targets, which might have been related to the pre-existence of double-negative subclones caused by mutation-mediated deficiency of DNA repair ( Yu et al., 2017 Yu et al., 2017 ; Shalabi et al., 2018 Shalabi et al., 2018 ). 3.1.2　Gene mutation 3 To some extent, CAR-T treatment is also an artificial selective pressure on tumor cells that magnifies the effects of adaptive capacity. Under CAR-T cell cytotoxicity, a small proportion of tumor cells may undergo secondary gene mutations that lead to antigenic epitope transformation, disturbance of antigen translocation onto the cell membrane, or antigen endocytosis, which helps tumor cells to avoid recognition by CAR-T cells (Figs. 2 2 a and 2 2 b). For the first time, scientists have identified acquired mutations in exons 2 and 4 of the CD19 gene accounting for CD19 protein loss, with hemizygous deletions in four patients resistant to CD19-directed CAR-T cell therapy (CART-19) ( Sotillo et al., 2015 Sotillo et al., 2015 ). Also, genetic mutations in CD19 exons 2 to 5 were found to induce loss-of-heterozygosity that produced a truncated protein with a nonfunctional or absent transmembrane domain. This consequently induced an irreversible loss of surface antigen and failure of CAR-T treatment in 12 patients with CD19-negative relapse ( Orlando et al., 2018 Orlando et al., 2018 ). Furthermore, the CD19 exon 2 was confirmed to be essential for the integrity of the CD19 transcript, and the frameshift mutation in exon 2 exhibited robust retention of intron 2 with a nonsense codon 40 amino acids downstream of the exon 2‍–‍intron 2 junction. This was consistent with findings in the same sample with no evidence of exon 2 skipping ( Asnani et al., 2020 Asnani et al., 2020 ). Moreover, point mutations in CD19 exon 3 can affect the epitope recognized by CD19 FMC63 CAR-T cells and induce CD19-positive relapse in patients with high-grade B-cell lymphoma. However, the same mutated tumor cells were able to be eradicated by the CD19 21D4 CAR-T cells with an alternative recognition epitope ( Zhang Z et al., 2020 Zhang Z et al., 2020 ). Homozygous B-cell maturation antigen ( BCMA ) gene deletion was also recognized theoretically as a risk factor in patients with multiple myeloma (MM) relapsing after anti-BCMA CAR-T cell therapy (da Vià et al., 2021). In this regard, a novel method involving detecting circulating tumor DNA (ctDNA) to simultaneously track multiple somatic mutations may facilitate our understanding of the distinct biological subtypes and genomic evolution patterns in relapsed tumor cells ( Scherer et al., 2016 Scherer et al., 2016 ). Moreover, ctDNA measurement can be used as a disease-monitoring tool following CAR-T cell treatment, as ctDNA was detectable at, or before, radiographic relapse in 94% of patients with disease progression ( Frank et al., 2021 Frank et al., 2021 ). 3.1.3　Alternative splicing 3 Alternative splicing is another common intrinsic factor which does not affect genome integrity during antigen-negative relapse ( Fig. 2 Fig. 2 c). Although genetic mutations in the exons of the CD19 gene influenced its protein expression and recognition by specific CAR-T cells, alternative splicing also contributed in nearly half of the patients with CD19 antigen-negative relapse from the same group ( Sotillo et al., 2015 Sotillo et al., 2015 ). Alternatively spliced CD19 messenger RNA (mRNA) species were found to produce a compromised CD19 epitope by splicing factor serine/arginine-rich splicing factor 3 (SRSF3)-mediated exon 2 skipping, which also generated a truncated CD19 variant that failed to trigger cytotoxicity by CD19 CAR-T cells ( Sotillo et al., 2015 Sotillo et al., 2015 ). Those isoforms pre-existed at diagnosis, again reflecting tumor heterogeneity ( Fischer et al., 2017 Fischer et al., 2017 ). 3.1.4　Lineage switch 3 During the hematopoiesis, diverse cell types are generated from hematopoietic stem cells (HSCs) through the process of fate determination. Under intrinsic factors and extrinsic signals, the lineage of cells is gradually restricted by a subsequent step of highly regulated differentiation, which is normally irreversible. However, leukemia cells can hijack this regulatory system and take advantage of lineage plasticity to avoid lineage-specific antigen targeting by CAR-T cells, resulting in resistance and relapse (Thankamony et al., 2021). Lineage switch is defined as a process by which leukemia cells convert into different lineages at relapse compared to the initial diagnosis, with a transformation of cell morphology and immune types. This is most commonly seen in pre-B leukemia ( Thoms et al., 2021 Thoms et al., 2021 ). Lineage-specific transcription factors, of which the most well-known is the mixed lineage leukemia (MLL) transcription factor, along with microenvironment signals participate in the lineage conversion of leukemia ( Hu et al., 2017 Hu et al., 2017 ). The acquisition of the CD19-negative myeloid phenotype was frequently seen in B-ALL patients with the MLL gene rearrangement ( Gardner et al., 2016 Gardner et al., 2016 ; Jacoby et al., 2016 Jacoby et al., 2016 ). In addition, a patient with R/R chronic lymphocytic leukemia (CLL) relapsed after CD19 CAR-T treatment, with a clonally related plasmablastic lymphoma that evaded lineage-specific targeting by means of multiple independent molecular genetic evolution events ( Evans et al., 2015 Evans et al., 2015 ). 3.1.5　Resistance to cell death 3 Resistance to cell death as a basic hallmark of cancer protects tumor cells from targeted eradication by the endogenous immune system. CAR-T cells exert cytotoxicity on tumor cells mainly in a death receptor-dependent manner. With the help of the innovative clustered regularly interspaced short palindromic repeats (CRISPR)-based genome-wide loss-of-function screening, scientists have discovered inherent resistance to CAR-T cell cytotoxicity by impaired cell death signaling, even with positive antigen expression ( Singh et al., 2020 Singh et al., 2020 ). Deficiency in apoptosis of tumor cells by loss of NADPH oxidase activator (NOXA), a B-cell lymphoma 2 (BCL2) family protein, was also reported in resistance to CAR-T cell therapy. Pharmacological augmentation of NOXA expression by histone deacetylase (HDAC) inhibitors dramatically sensitized tumor cells to CAR-T cell-mediated clearance ( Yan X et al., 2022 Yan X et al., 2022 ). 3.2 CAR-T cells 2 The CAR-T cell is a genetically engineered T cell coupled with a synthetic antigen-specific receptor that recognizes cell surface antigens on tumor cells in a major histocompatibility complex (MHC)-independent manner. Tumor relapse is closely associated with the compromised function and persistence of CAR-T cells in vivo. Long-term follow-up revealed higher peak blood levels of CAR-T cells to be positively correlated with a longer duration of response (DOR) ( Cappell et al., 2020 Cappell et al., 2020 ). Surprisingly, two patients with CLL sustained CR with CAR-T cells remaining detectable for a decade after infusion. This was attributed to a persistent highly-activated CD4 + CAR-T cell population with cytotoxic characteristics. This suggests that the long-term potential and clonal stability of CAR-T cells play a vital role in relapse-free durable remission ( Melenhorst et al., 2022 Melenhorst et al., 2022 ). However, by combining single-cell RNA sequencing (scRNA-seq) and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), a deficiency of T helper 2 function was predictable and associated with CD19-positive relapse in CD19 CAR-T cell products from 12 R/R ALL patients ( Bai et al., 2022 Bai et al., 2022 ). Therefore, CAR-T cell functional characteristics determined by the CAR design and manufacturing process can significantly affect the risk of relapse and long-term outcome. 3.2.1　CAR design 3 The CAR structure consists of an antigen-recognition single-chain variable fragment (scFv), a linker molecule, a transmembrane domain, and a costimulatory domain. The components integrated in the CAR design have fundamental effects on CAR-T cell function. Further refinement and manipulation of biophysical parameters in CAR design would enhance the quality of signaling and improve the precise tuning of CAR-T cell activity. 3.2.1.1　Antigen target design 4 Appropriate selection of the antigen target is crucial to the safety and efficacy of CAR-T cell therapy. The tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) are limited in B-cell malignancies. Widely used suitable targets for B-cell leukemia and lymphoma currently include only CD19, CD20, and CD22. For patients with antigen-negative relapse after several rounds of CAR-T treatment, more rigorous therapies are needed. Combinatorial autocrine-based selection to rapidly identify specific ligands for B-cell receptors on the surface of tumor cell may realize personalized treatment and prevent relapse ( Stepanov et al., 2018 Stepanov et al., 2018 ). The powerful high-throughput genome-wide CRISPR-screening technology may facilitate the discovery of more suitable and effective antigen targets for CAR-T cell therapy ( Ancos-Pintado et al., 2022 Ancos-Pintado et al., 2022 ). 3.2.1.2　Recognition pattern 4 CAR is a receptor empirically designed to mimic and simplify natural T cell receptor (TCR) function. However, CAR may also have some shortcomings compared to traditional TCR in some respects. TCR recognizes antigens in an MHC-restricted mechanism, but with at least 100-fold more sensitivity to an antigen than CAR ( Salter et al., 2021 Salter et al., 2021 ). Moreover, natural TCR bears intact signaling domains, whereas CAR typically incorporates a single TCRζ in the signaling element ( Majzner and Mackall, 2018 Majzner and Mackall, 2018 ). Therefore, the density of target antigens may affect the transduction strength of activation signaling in CAR-T cells. The low density of either antigen on tumor cells or CAR on CAR-T cells significantly impairs the anti-tumor efficacy, suggesting that the stoichiometric relationship affects the functionality of CAR ( Walker et al., 2017 Walker et al., 2017 ). Up-regulating CD22 expression rather than increasing CAR affinity contributes to improved CAR-T cell functionality and persistence in B-cell malignancies ( Ramakrishna et al., 2019 Ramakrishna et al., 2019 ; Yang et al., 2021 Yang et al., 2021 ). In addition, the divergent antigen-binding affinity between CAR and TCR contributes to the variant formation and quality of immune synapse during antigen recognition ( Harris et al., 2018 Harris et al., 2018 ). The CAR-T cell immune synapse in lack of lymphocyte function-associated antigen-1 (LFA-1) adhesion rings leads to more rapid induction and faster detachment from the target cell, which may explain the more intensive cytotoxicity exerted by CAR-T cells ( Davenport et al., 2018 Davenport et al., 2018 ). In conclusion, CAR-T cells exhibit more rapid and vigorous cytotoxicity by means of MHC-unrestricted recognition, but can target only cell surface antigens, and their functionality is affected by the surface density on both sides. On the other hand, TCR-T cells with MHC-associated specificity and sensitivity to tumor antigens are safer and less influenced by antigen modulation or variation, but it is hard to develop a universal product. Which type of receptor is superior in the control of tumor relapse is currently unknown. 3.2.1.3　Signaling transduction domains 4 The costimulatory domain in the CAR construct is another fundamental element that dominates transduction of activation signaling and greatly influences CAR-T cell function. CD28 or 4-1BB costimulatory domains are most widely used in CAR-T cell therapy ( Ying et al., 2019 Ying et al., 2019 ). CAR-T cells with a CD28 domain exert a swifter and stronger cytotoxic response, but with less persistence due to apparent exhaustion ( Savoldo et al., 2011 Savoldo et al., 2011 ). In contrast, CAR-T cells with a 4-1BB domain exhibit moderate functionality while maintaining long-term sustainability ( Long et al., 2015 Long et al., 2015 ; Guedan et al., 2018 Guedan et al., 2018 ). The non-signaling extracellular spacer domain, also known as the linker molecule, is also important for CAR-T cell anti-tumor activity in vivo ( Hudecek et al., 2015 Hudecek et al., 2015 ; Alabanza et al., 2017 Alabanza et al., 2017 ). The length and composition of immunoglobulin G (IgG)-derived extracellular spacer domains may influence the interaction between the Fc domain within the spacer and the Fc receptor-bearing host myeloid cells, which brings activation-induced T-cell death (AICD) and CAR-T cell clearance. By modifying distinct regions in the CH2 domain to abrogate binding to Fc receptors, in vivo persistence and anti-tumor effects of CAR-T-cells can be improved. Finally, the immunogenicity of scFv in CAR can cause host immunological rejection by anti-CAR antibody production, leading to the eventual failure of CAR-T cell therapy ( Maus et al., 2013 Maus et al., 2013 ). 3.2.2　CAR-T cell manufacture 3 A favorable clinical response to CAR-T cell therapy requires both well-functioning autologous or donor-derived T cells and a manufacturing process with quality control. Patients with B-cell malignancies already have a compromised or dysregulated immune system. An impaired immune system can result in a decrease in immunological diversity, and an increase of senescent T cells may promote cancer progression. Most patients receive multiple lines of chemotherapy before CAR-T cell apheresis. These factors may profoundly affect autologous T cells, leading to worse CAR-T cell function. Moreover, CAR-T cells are usually cultured in a medium with complete nutrition and additional cytokines and growth factors to improve ex vivo expansion before reinfusing into patients. However, such culture systems are so specialized that CAR-T cells may not be well-adapted to the in vivo hostile microenvironment shaped by tumor cells. Tumor cells compete to uptake glucose, amino acids, glutamine, fatty acids, and other growth factors, thereby interfering the normal energy production and protein synthesis in CAR-T cells. In the meantime, the metabolic production of lactase and reactive oxygen species would dampen the function and persistence of CAR-T cells ( Xia et al., 2021 Xia et al., 2021 ). Therefore, the lack of metabolic rewiring in CAR-T cells during ex vivo culture compromises their capacity to meet their energetic and anabolic demands when countering the TME, which fails to exert durable anti-tumor efficacy in patients. Even worse, the contamination of leukemia cells during the manufacturing process of CAR-T cells may result in accidental transfection of CAR genes into leukemia cells, which increases the risk of tumor resistance and eventual relapse ( Ruella et al., 2018 Ruella et al., 2018 ). In addition, clonal expansion of CAR-T cells due to accidental lentivector integration in the Casitas B-lineage lymphoma ( CBL ) gene has raised the risk of carcinogenic insertional mutagenesis ( Shah et al., 2019 Shah et al., 2019 ). Therefore, a safer and more efficient process for manufacturing CAR-T cells is urgently needed to ensure better clinical efficacy. 3.2.3　CAR-T cell functional defects 3 CAR-T cells have unique biological functions compared to conventional T cells due to the presence of the CAR. Although CAR-T cells overcome the restriction of MHC-dependent antigen recognition, most biological behaviors related to CAR signaling remain unknown. It is believed that CAR-T cell exhaustion due to antigen stimulation or self-clustering tonic signaling contributes most to the impaired function and shortened persistence of CAR-T cells in vivo, and epigenetic reprogramming actively reshapes its differentiation fate. 3.2.3.1　CAR-T cell exhaustion 4 Constitutive ligand-dependent CAR activation induces an exhaustive phenotype in CAR-T cells, manifested as decreased proliferation, impaired cytotoxicity, shortened survival, terminal differentiation, and reduced persistence. In parallel, ligand-independent self-clustering of CAR scFv triggers CAR CD3-z phosphorylation ( Long et al., 2015 Long et al., 2015 ) and downstream tonic signaling that accelerates CAR-T cell exhaustion, and impairs anti-tumor effects in the absence of antigen exposure ( Calderon et al., 2020 Calderon et al., 2020 ). This effect is more obvious in CAR-T cells with a high density of CARs on the surface ( Walker et al., 2017 Walker et al., 2017 ). Recently, an extraordinary behavior was discovered: CAR-T cells transferred the target antigen from tumor cells to themselves by trogocytosis, leading to fratricide CAR-T cell killing and exhaustion, and facilitating immune escape through reversible antigen loss on tumor cells and inducible inhibitory receptors on CAR-T cells ( Hamieh et al., 2019 Hamieh et al., 2019 ). Much effort has been devoted to understanding the molecular characteristics associated with CAR-T cell exhaustion ( Ajina and Maher, 2018 Ajina and Maher, 2018 ). The transcription factor, nuclear factor of activated T cell (NFAT), is important for CAR-T cell activation downstream of the CD28 costimulatory domain ( Macian, 2005 Macian, 2005 ). CD8 + CAR-T cells exhibited high expression of inhibitory receptors programmed cell death protein-1 (PD-1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) associated with secondary NFAT-initiated activation of the nuclear receptor transcription factor nuclear receptor 4 group A (NR4A) family, similar to endogenous tumor-infiltrating CD8 + lymphocytes ( Chen J et al., 2019 Chen J et al., 2019 ). Further investigation discovered that epigenetic thymocyte selection-associated high mobility group box (TOX) transcription factors downstream of NFAT cooperatively contributed to T cell exhaustion with NR4A ( Khan et al., 2019 Khan et al., 2019 ; Seo et al., 2019 Seo et al., 2019 ). 3.2.3.2　Epigenetic reprogramming 4 Studies have shown that epigenetic reprogramming is involved in regulating the transcription and expression of T cell depletion and memory-related genes ( Pauken et al., 2016 Pauken et al., 2016 ; Sen et al., 2016 Sen et al., 2016 ). Under continuous antigen stimulation, T cells will gradually start DNA methylation, reducing their memory potential and killing ability ( Ghoneim et al., 2017 Ghoneim et al., 2017 ). To investigate epigenetic effects on CAR-T cell depletion and function, researchers performed longitudinal genome-wide DNA methylation analysis on CD19 CAR-T cells in patients with B-ALL. CAR-T cells were found to undergo repression of genes associated with memory potential and exhaustion DNA methylation programming, including TOX ( Zebley et al., 2021 Zebley et al., 2021 ). As the treatment went on, CAR-T cells showed a decreased expansion ability, increased methylation levels of memory-related genes, and gradually demethylated exhaustion-related genes, leading to the overall transition to CAR-T cell depletion. In addition, transient inhibition of CAR signaling reversed CAR-T cell depletion through epigenetic remodeling ( Weber et al., 2021 Weber et al., 2021 ). These studies indicated a complex regulatory network involved in CAR-T cell functional defects at the both the genetic and epigenetic levels. 3.3 Tumor microenvironment 2 Setting aside the interplay between CAR-T cells and tumor cells alone, a complex interactive network in the TME greatly affects the behavior of both types of cells. Various inhibitory immune or stromal cells within the TME antagonize CAR-T cell cytotoxicity, but support the senescence and survival of tumor cells. Aberrant chemotaxis attracts tumor cell migration and retention, but blocks CAR-T cell trafficking. A hypoxic and nutrition-deprived metabolic environment favors tumor cell behavior, while threatening CAR-T cell function and survival. Accumulating evidence suggests that the immunosuppressive milieu of the TME contributes enormously to relapse after CAR-T cell therapy ( Gaudichon et al., 2019 Gaudichon et al., 2019 ; Yan et al., 2019 Yan et al., 2019 ). 3.3.1　Inhibitory cellular components 3 The heterogenous population of inhibitory cells in the TME affecting tumor relapse consists mainly of tumor-associated macrophages (TAMs), mesenchymal stem cells (MSCs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) ( Sterner and Sterner, 2021 Sterner and Sterner, 2021 ). These inhibitory cells may share several similar mechanisms of immunosuppression of CAR-T cells. Macrophages can be functionally classified into subtypes M1 and M2, depending on their localization and surrounding environment, with the ability to perform mutual conversion ( Chen C et al., 2020 Chen C et al., 2020 ). In brief, M1 macrophage is involved in immune defense against infection and cancer through phagocytosis and secretion of pro-inflammatory cytokines, such as tumor necrosis factor‍-‍α (TNF‍-‍α), interleukin-‍1 (IL‍-‍1), and IL-6. In contrast, M2 macrophage takes part in tissue repair and immune tolerance ( Kadomoto et al., 2021 Kadomoto et al., 2021 ). Increased TAM infiltration was found positively related to a short remission period and high relapse risk, with CD68 expression indicating an M2 phenotype ( Yan et al., 2019 Yan et al., 2019 ). Tumor interferon (IFN) signaling is correlated with macrophage content in the TME while exerting suppression on CAR-T cells by up-regulating programmed cell death-ligand 1 (PD-L1) and MHC-II on the tumor cell surface ( Jain et al., 2021 Jain et al., 2021 ). Therefore, TAMs commonly associated with the M2 subtype contribute to tumor relapse after CAR-T cell therapy. MSCs are multipotent stem cells found mainly in the bone marrow where they serve an immunomodulation function ( Li and Hua, 2017 Li and Hua, 2017 ). MSCs can inhibit T cell proliferation, induce apoptosis, and promote polarization into Tregs under stimulation by pro-inflammatory cytokines ( Regmi et al., 2019 Regmi et al., 2019 ). MSCs also influence the CAR-T cell subpopulation and cytokine release through the galectin family, IL-10, and transforming growth factor-‍β (TGF-‍β) ( Guerrouahen et al., 2019 Guerrouahen et al., 2019 ). However, a recent study reported that bone marrow MSCs from pediatric patients with B-ALL highly suppressed T-cell responses, but did not compromise CD19 CAR-T cell activity ( Zanetti et al., 2020 Zanetti et al., 2020 ). Further investigations are needed to determine the precise effect of MSCs on CAR-T cell efficacy. MDSCs consist of heterogeneous myeloid progenitors, including immature macrophages, granulocytes, and dendritic cells (DCs). MDSCs are known to suppress cytotoxic T lymphocyte (CTL) proliferation and function through up-regulated expression of the inhibitory molecule PD-L1 ( Wang et al., 2017 Wang et al., 2017 ). They are accumulated in tumors in response to various cytokines and growth factors ( Lindo et al., 2021 Lindo et al., 2021 ). Intriguingly, MDSCs may originate and remain in the same place where leukemia and lymphoma reside, and exert antigen-independent suppression on T cells ( Kumar et al., 2016 Kumar et al., 2016 ). Whether MDSCs contribute to tumor relapse after CAR-T cell therapy needs further validation. Tregs are CD4 + CD25 + T cells suppressing auto-reactive T cells to prevent an excessive immune response and maintain homeostasis ( Sakaguchi et al., 2006 Sakaguchi et al., 2006 ; Langier et al., 2010 Langier et al., 2010 ). This function relies on the master transcription factor forkhead box P3 (FOXP3). TGF-‍β is also a critical factor for the generation of Tregs ( Yang et al., 2008 Yang et al., 2008 ). Increased frequencies of Tregs in circulating peripheral blood were observed in leukemia patients, consistent with their reduced remission rates following chemotherapy. Therefore, in regard to the prominent role of Tregs in immunosuppression and tumor escape, routine lymphodepletion regimens, including fludarabine and cyclophosphamide, are given before CAR-T cell infusion to eliminate Tregs and other inhibitory cells. The exact role of Tregs in affecting the long-term outcomes after CAR-T cell therapy is still unclear. 3.3.2　Chemotaxis 3 Despite direct immunosuppression of CAR-T cell function, the same inhibitory cells along with other stromal cells also create a conditional chemotaxis that favors tumor cell migration, retention, and resistance, while compromising CAR-T cell trafficking and approach. This aspect is most apparent in leukemia relapse in the bone marrow, testis, and CNS where the CXC chemokine ligand 12 (CXCL12)/CXC chemokine receptor 4 (CXCR4) axis contributes most. CXCL12 was first discovered as an important chemokine in the bone marrow for HSC quiescence, retention, and homeostasis ( Pinho and Frenette, 2019 Pinho and Frenette, 2019 ). Later, the CXCL12/CXCR4 axis was found to be involved in the pathogenesis of B-cell leukemia, promoting leukemia cell homing, survival, and proliferation in the bone marrow ( Colmone et al., 2008 Colmone et al., 2008 ; Peled et al., 2018 Peled et al., 2018 ). A similar chemotaxis also plays an important role in the CNS infiltration of leukemia cells ( Williams et al., 2016 Williams et al., 2016 ). CAR-T cells lacking CXCR4 exhibit poor migration and retention in the bone marrow, let alone trafficking into the CNS with its physical barrier, the blood‍‒‍brain barrier (BBB). However, recent clinical trials proved the safety and efficacy of CD19 CAR-T cell therapy with a high response rate in patients with CNS leukemia and lymphoma ( Siddiqi et al., 2021 Siddiqi et al., 2021 ; Tan et al., 2021 Tan et al., 2021 ; Qi et al., 2022 Qi et al., 2022 ). This suggests that there may be other possible mechanisms for the CNS infiltration of CAR-T cells. 3.3.3　Metabolism 3 Hypoxic and nutrition-deprived metabolic environments, especially in the bone marrow and CNS, compromise CAR-T cell function and contribute to tumor resistance and relapse ( Wilson and Hay, 2011 Wilson and Hay, 2011 ). Under hypoxia, tumor cells adapt by progressing transcriptional reprogramming through the master regulator hypoxia-inducible factor-1α (HIF-1α) ( Jing et al., 2019 Jing et al., 2019 ). However, oxygen is essential for CAR-T cell proliferation and cytotoxicity through oxidative phosphorylation in mitochondria ( van Bruggen et al., 2019 van Bruggen et al., 2019 ). Apart from the oxygen deficiency in the TME, hematological tumor cells catabolize the semi-essential amino acid arginine to drive cell proliferation. CAR-T cells are susceptible to the low arginine microenvironment due to the low expression of the arginine resynthesis enzymes argininosuccinate synthase (ASS) and ornithine transcarbamylase (OTC) ( Fultang et al., 2020 Fultang et al., 2020 ). Recent application of scRNA-seq technology will help bring insights into the heterogeneity and dynamics of immune cells in the TME ( Ren et al., 2021 Ren et al., 2021 ), as well as context-dependent metabolic divergence during CAR-T cell therapy and other immunotherapies (Artyomov and van den Bossche, 2020). 4 Future approach to surmount relapse after CAR-T cell therapy in B-cell malignancies 1 Future approaches to address or prevent relapse after CAR-T cell therapy in B-cell malignancies are destined to involve multiple aspects in accordance with the nature of tumor cells themselves, the properties of CAR-T cells, and the landscape within the specific TME. Developing suitable preclinical evaluation models will provide deep insights into the mechanisms behind tumor relapse and indicate CAR-T cell therapeutic potency in the clinic ( Si et al., 2022 Si et al., 2022 ). 4.1 Optimized antigen targeting 2 The optimization of antigen targeting is always a focus of CAR-T cell therapy, to achieve better tumor recognition and reduce adverse effects. 4.1.1　Novel target 3 Discovering novel surface antigens during lineage-specific commitment of B cells will compensate for the limited selection of TSAs and TAAs available for CAR-T cell therapy ( Huang et al., 2020 Huang et al., 2020 ). Targeting CD22, another surface protein involved in the regulation of B-cell antigen receptor signaling, has induced CR in patients with LBCL who relapsed after CD19 CAR-T cell therapy ( Fry et al., 2018 Fry et al., 2018 ; Baird et al., 2021 Baird et al., 2021 ). CD30 in Hodgkin lymphoma is also under investigation as a promising candidate for CAR-T cell therapy ( Ramos et al., 2020 Ramos et al., 2020 ). Surface antigen CD37 expressed in B-cell non-Hodgkin lymphomas, CLL, and even cutaneous or peripheral T-cell lymphoma is a suitable target. CD37 CAR-T cells demonstrated antigen-specific activation, cytokine production, and cytotoxic activity against two different lymphoid lineages, without evidence of significant T-cell fratricide ( Scarfò et al., 2018 Scarfò et al., 2018 ). Moreover, CD70 and CD123 are both indicated during relapse with lineage switch after traditional CAR-T cell therapy, suggesting that they may have value as novel targets ( Muñoz et al., 2001 Muñoz et al., 2001 ; Shaffer et al., 2011 Shaffer et al., 2011 ). Although a novel target-directed CAR-T cell therapy may not work in the clinic or work only in certain types of B-cell malignancies, promoting clinical translation and discovering more potential targets are still of great potential benefit to patients. 4.1.2　Multiple targeting 3 Sequential infusion of CAR-T cells with alternative targets or using dual-target and multi-target CAR-T products in the beginning may overcome antigen-negative relapse ( Fig. 3 Fig. 3 ). A dual targeting strategy can be achieved through either a bicistronic vector to allow expression of two different CARs on the same cell, co-transduction to encode two CAR constructs via transduction with multiple vectors, or tandem transduction to encode two CARs on the same chimeric protein using a single vector. As tumor cells may progress into antigen-negative relapse following treatment with a single-target CAR-T cell product, these methods providing alternative targets combined with the original would reduce the chance of immune escape to a great extent. In particular, a tandem CAR (TanCAR) with a proof-of-concept of Boolean “OR”-gated signal computation can recognize either of the targets and sufficiently trigger CAR-T cell activation, thereby overcoming antigen escape-mediated relapse after single target-directed therapy ( Tong et al., 2020 Tong et al., 2020 ). A CD19/CD20-bispecific CAR efficiently prevents antigen escape by malignant B cells ( Zah et al., 2016 Zah et al., 2016 ). A tandem CD19/CD20 CAR effectively lessens the chance of leukemic escape mutations and prevents relapse, with minimal toxic effects ( Schneider et al., 2017 Schneider et al., 2017 ). A CD19/CD22-bispecific or cocktail CAR-T cell therapy exhibited high durable CR rates and favorable safety profiles in both R/R B-ALL and B-cell lymphoma ( Dai et al., 2020 Dai et al., 2020 ; Cao et al., 2021 Cao et al., 2021 ; Yan N et al., 2022 Yan N et al., 2022 ). Interestingly, a recent tri-specific CD19×CD20×CD22 variable domain of heavy chain of heavy-chain antibody (VHH) CAR-T cell (LCAR-AIO) therapy efficiently eradicated antigen-heterogeneous B-cell tumors, with enhanced expansion and prolonged persistence in preclinical in vivo models. This indicates a potential capacity to treat patients with prior relapse after CD19 CAR-T cell therapy ( Zhou Z et al., 2021 Zhou Z et al., 2021 ). Targeting markers associated with lineage switch, such as CD70 or CD123, combined with a conventional CD19 target, is a promising compound strategy to overcome antigen-negative relapse ( Ruella et al., 2016 Ruella et al., 2016 ; Tu et al., 2019 Tu et al., 2019 ; Yan et al., 2020 Yan et al., 2020 ). 4.2 Enhanced CAR-T cell function 2 Although currently approved commercial CAR-T products with second-generation CARs have shown great clinical efficacy, limitations still exist. Therefore, the engineering of CAR-T cells based on precise modulation of CAR design and enhancement on multiple levels represents a new strategy to reduce CAR-T cell functional defects and overcome relapse. 4.2.1　CAR construct 3 The selection and induction of additional optimal costimulatory domains, such as OX40, inducible T-cell co-stimulator (ICOS), and CD27 in third-generation CARs, have greatly enhanced cytotoxicity and prolonged persistence compared with those of the second generation ( Enblad et al., 2018 Enblad et al., 2018 ; Roselli et al., 2021 Roselli et al., 2021 ). Furthermore, the production of fourth-generation CARs, involving fusion of extra cytokines or antibodies into the CAR construct, may enhance CAR-T cell activation, proliferation, and anti-tumor activity by modulating the specific TME ( Adachi et al., 2018 Adachi et al., 2018 ; Chen YH et al., 2019 Chen YH et al., 2019 ; Hong et al., 2020 Hong et al., 2020 ; Webster et al., 2021 Webster et al., 2021 ). CAR-T cells overexpressing IL-15 showed strong proliferation, persistence, and antitumor activity in patients with B-ALL ( Sun et al., 2021 Sun et al., 2021 ). Co-expression of IL-7 and C-C motif chemokine ligand 19 (CCL19) induces the infiltration of peripheral T cells and DCs into the tumor, and improves the memory responses of recipient T cells and administrated CAR-T cells against tumors ( Adachi et al., 2018 Adachi et al., 2018 ). The autocrine signaling of checkpoint inhibitors ( Li et al., 2017 Li et al., 2017 ; Rafiq et al., 2018 Rafiq et al., 2018 ) and the intrinsic knockout of inhibitory receptors by CRISPR/CRISPR-associated protein 9 (Cas9) gene editing ( Hu et al., 2019 Hu et al., 2019 ) are promising approaches to resist the immunosuppressive tumor milieu. Spatiotemporal regulation of the magnitude of CAR expression is functionally beneficial, as constitutive CAR activation signaling leads to the exhaustion of CAR-T cells. Antigen-regulated self-driving CD19 CARs with additional dominant negative TGF-‍β expression under transcriptional control of synthetic activating protein-1 (AP-1), nuclear factor-‍κB (NF-‍κB), and signal transducer and activator of transcription 5 (STAT5) promoters enhance tumor-dependent activation and limit exhaustion in B-cell lymphoma models ( Webster et al., 2021 Webster et al., 2021 ). 4.2.2　CAR-T persistence 3 Multi-dimensional assessment of CAR-T cell infusion products may identify potential mechanisms related to durable remission or relapse. Molecular factors in the pre-manufacture of T cells also provide insights into the long-term persistence of CAR-T cell therapy ( Chen et al., 2021 Chen et al., 2021 ). Comprehensive evaluation by performing bulk RNA-seq or scRNA-seq assay for transposase-accessible chromatin sequencing (ATAC-seq) and CITE-seq helps unveil genomic, epigenomic, and functional characteristics that determine therapeutic responses and clinical outcomes ( Fraietta et al., 2018a Fraietta et al., 2018a ; Deng et al., 2020 Deng et al., 2020 ). Alterations in chromatin accessibility and conformation reveal a dynamic regulatory landscape in CAR-T cell exhaustion during ex vivo expansion ( Gennert et al., 2021 Gennert et al., 2021 ). Joint profiling of chromatin accessibility and random integration sites of CAR lentivirus may discover essential gene regulation associated with durable treatment ( Wang et al., 2020 Wang et al., 2020 ). Targeting the epigenome improves the memory phenotype and persistence of CAR-T cells. Sequencing results of CAR-T cells at the stage of peak response showed that the insertion of a CAR gene into the ten-eleven translocation 2 ( TET2 ) gene induced unfunctional methylcytosine dioxygenase and inhibition of exhaustion ( Fraietta et al., 2018b Fraietta et al., 2018b ). CAR-T cells with TET2 knockdown showed similar epigenetic characteristics to those at peak response, with a high memory phenotype and strong killing ability. DNA methyltransferase 3α (DNMT3A) is another important epigenome target that drives CAR-T depletion. DNMT3A knockout in CAR-T cells enhanced proliferation and maintained long-term memory, which improved efficacy during CLL treatment ( Prinzing et al., 2021 Prinzing et al., 2021 ). In addition, continuous expression of c-Jun in T cells enhanced CAR-T cell function ( Lynn et al., 2019 Lynn et al., 2019 ). More recently, inhibition of overactivated calcium signaling involved in tonic signaling rendered CAR-T cells resistant to exhaustion, thereby enhancing anti-tumor efficacy ( Shao et al., 2022 Shao et al., 2022 ). Histone acetylation, histone methylation, and DNA-binding proteins in epigenetic genomes also affect CAR-T cell function. Moreover, specific knockout of transcription factors, such as transducin-like enhancer of split 4 (TLE4) and IKAROS family zinc finger 2 (IKZF2) based on genome-wide CRISPR screening, promoted CAR-T cell effector function and inhibited CAR-T cell exhaustion ( Wang DR et al., 2021 Wang DR et al., 2021 ). Equally, novel modulator genes and biomarkers of malignant transformation in tumor cells could be identified and used as new therapeutic targets in combination with CAR-T cell therapy to prevent tumor relapse ( Ancos-Pintado et al., 2022 Ancos-Pintado et al., 2022 ). 4.2.3　CAR-T manufacture 3 Optimization of the manufacturing process of CAR-T cells is essential for improving anti-tumor efficacy in vivo. Resolving the immunomodulatory metabolic landscape based on the stable isotope-resolved metabolomics (SIRM) ( Fan et al., 2016 Fan et al., 2016 ) and metabolomics-edited transcriptomic analysis (META) ( Fan et al., 2005 Fan et al., 2005 ) may improve metabolic complements during the manufacturing process of CAR-T cells ( Xu et al., 2019 Xu et al., 2019 ). This may help ameliorate CAR-T cell metabolic fitness and overcome metabolic derangement and stress in the TME. Developing ex vivo models to simulate the TME for drug screening helps improve the therapeutic effect of CAR-T cells after infusion. A three-dimensional (3D) TME-mimicry culture was developed to study TAM modulation of T-cell-based cancer immunotherapy within the TME, and validated the efficacy of PD-1/PD-L1 and monoamine oxidase-A (MAO-A) blockade therapies ( Li et al., 2022 Li et al., 2022 ). In addition, organoid systems also provide a novel strategy for high-throughput drug screening by simulating the TME. Patient-derived breast tumor samples were isolated into single cells to generate tumor organoids, which were further co-cultured with CD8 + T cells to study the effects of epigenetic inhibitors on the anti-tumor activity of T cells ( Zhou ZL et al., 2021 Zhou ZL et al., 2021 ). To avoid rejection by the host immune system, replacement of murine-origin CAR scFv with a fully humanized form reduced immunogenicity and prolonged CAR-T cell persistence. Inventing universal CAR-T cells by transcription activator-like effector nuclease (TALEN) or CRISPR/Cas9-mediated knockout of TCR, CD52, and human leukocyte antigen (HLA) in T cells from healthy donors has hugely improved product quality for high tumor-burden patients with urgent need ( Hu et al., 2021 Hu et al., 2021 ). This may help overcome the functional deficiency of pre-manufactured autologous T cells. Discovering alternative cell sources for the sufficient production of CAR-T cells may help shorten the period of manufacture and improve clinical efficacy. Exploring CAR-T cell production from induced pluripotent stem cells (iPSCs) or replacing chassis cells may enhance leukemia cell clearance in vivo ( Zhang L et al., 2020 Zhang L et al., 2020 ; Rafei et al., 2021 Rafei et al., 2021 ; Sadeqi Nezhad et al., 2021 Sadeqi Nezhad et al., 2021 ). Developing split, universal, and programmable (SUPRA) CAR-T cells capable of target switch and response control to enhance recognition and diminish side effects is a promising approach for the future. 4.3 Combinational treatment strategies 2 We may also look ahead to resolving relapse after CAR-T cell therapy by combining treatment strategies, including application of checkpoint inhibitors and small molecule compounds, disruption of tumor cell chemotaxis or enhancement of CAR-T cell trafficking, and stimulation of the endogenous anti-tumor immune response ( Fig. 4 Fig. 4 ). 4.3.1　Immune checkpoint inhibitor 3 The combination of a monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and CAR-T cell therapy has proven to be safe and effective in treating hematologic malignancies ( Wang et al., 2019 Wang et al., 2019 ). The traditional PD-1-blocking antibody, pembrolizumab, ameliorated tumor progression, induced a clinically significant anti-tumor response, and significantly prolonged progression-free survival (PFS) in patients with diffusive LBCL and patients with transformed follicular lymphoma (tFL) ( Chong et al., 2017 Chong et al., 2017 ; Zheng et al., 2021 Zheng et al., 2021 ). CAR-T cells armored with secreting PD-1-blocking scFv in both a paracrine and autocrine manner improved efficacy in clinically relevant syngeneic and xenogeneic mouse models of PD-L1 + hematologic and solid tumors ( Rafiq et al., 2018 Rafiq et al., 2018 ). 4.3.2　Small molecule compounds 3 In recent years, the enhancement of CAR-T cell function by epigenetic small molecule inhibitors has continued to attract attention. Decitabine, a DNA methylase inhibitor, reversed exhaustion-related DNA methylation, improved CD123 CAR-T cell proliferation and memory phenotype, and enhanced CD123 CAR-T cell cytotoxicity ( You et al., 2020 You et al., 2020 ). Low-dose decitabine-treated CD19 CAR-T cells maintained high expression of memory-related genes and low expression of exhaustion-related genes. Acquired enhanced proliferation and increased pro-inflammatory cytokine secretion all enhanced CAR-T cell anti-tumor activity ( Wang Y et al., 2021 Wang Y et al., 2021 ). Chidamide, an HDAC inhibitor, has been reported to promote CD22 expression on the surface of B-cell lymphoma, thereby enhancing CD22 CAR-T cell targeting in vivo ( Yang et al., 2021 Yang et al., 2021 ). Bromodomain and extra-terminal (BET) inhibitor treatment with CAR-T cells also promoted proliferation, reversed exhaustion, and enhanced efficacy in B-cell lymphoma ( Kong et al., 2021 Kong et al., 2021 ). The use of bioactive materials during CAR-T cell culture and the combination of small molecular compounds to reverse the exhaustion state and prolong persistence are also applicable ( Bao et al., 2021 Bao et al., 2021 ). 4.3.3　Chemotaxis 3 Targeting the chemotaxis landscape of the TME within the most favorable relapse sites by remodeling the intracellular signaling transduction of chemokine receptors on CAR-T cells or by the combinational use of chemokine receptor blockers to leukemia cells improves CAR-T cell migration and restrains leukemia cell retention, extending immune surveillance and preventing leukemia relapse. As the CXCL12/CXCR4 axis plays an essential role in the bone marrow and CNS relapse of leukemia, it offers a potential therapeutic target. High expression of CXCR4 on ALL blasts has been shown to be a predictor of poor prognosis ( Cancilla et al., 2020 Cancilla et al., 2020 ). However, CXCR4 expression is drastically down-regulated in cytokine-induced killer (CIK) cells. Over-expression of CXCR4 in CD33 CAR-T cells facilitated the homing of CAR-CIKs to the bone marrow and subsequent leukemia eradication ( Biondi et al., 2021 Biondi et al., 2021 ). Although a B-ALL xenografted mouse model treated with CXCR4 antagonist plerixafor reduced engraftment into the bone marrow and liver, it failed to prevent the infiltration of tumor cells into the CNS, which suggested that other chemotaxis or mechanisms might mediate such behavior ( Williams et al., 2016 Williams et al., 2016 ). Further exploration of the role of the CXCL12/CXCR4 axis, as well as other chemotaxis, in B-cell malignancy relapse after CAR-T cell therapy would broaden our therapeutic strategies to simultaneously target the TME. 4.3.4　Endogenous immune activation 3 Although few studies have comprehensively examined the characteristics of the intact TME due to a lack of analysis technologies, a recent study involving multiplex immunostaining and in-situ hybridization (ISH) assays found activation of CAR and non-CAR-T cells within the TME following CAR-T cell therapy ( Chen PH et al., 2020 Chen PH et al., 2020 ). Another study using scRNA-seq revealed substantial modification of the TME during CAR-T cell therapy. IFN-γ produced by CAR-T cells not only enhanced endogenous T and natural killer cell activity, but was also essential for sustaining CAR-T cell cytotoxicity. CAR-T cell-derived IFN-γ facilitated host IL-12 production, supporting both the host immune and CAR-T cell responses ( Boulch et al., 2021 Boulch et al., 2021 ). It is possible that specific CAR-T cell cytotoxicity induced epitope spreading of TCR, which activated recruitment of DCs and endogenous T cells into the TME. These findings suggest a cross-talk between CAR-T cell subsets and the TME is essential for sustained cytotoxic activity. Potential strategies to activate the anti-tumor response of the endogenous immune system combined with CAR-T cell therapy may help overcome relapse and maintain long-term remission. 5 Future perspectives 1 CAR-T cell therapy is a novel and rapidly evolving cellular immunotherapy that has achieved significant long-term durable remission in cancer patients compared to traditional cancer therapies. Although CAR-T cell therapy shows remarkable clinical efficacy in the treatment of B-cell malignancies, tumor relapse remains a major obstacle that hinders its broad application. Intratumor heterogeneity as a natural intrinsic factor fosters tumor evolution under selective pressure. Metabolic reprograming and dynamic interplay between tumor cells and the microenvironment provide tumor cells with superior adaptability for survival under stress by specific therapy. CAR-T cells with flaws in CAR design and functional defects may reduce anti-tumor efficacy and durable remission. Moreover, a hostile metabolic and immunoinhibitory landscape in the TME compromises CAR-T cell function while favoring tumor cell survival, escape, and relapse. To confront immune escape and tumor relapse, upgraded CAR-T cells with optimized antigen recognition and enhanced function and combinational treatment strategies would facilitate precise targeting and overcome an immunosuppressive milieu. Note that “while the priest climbs a post, the devil climbs ten”: every promising therapy might also drive tumor evolution, as suggested by Darwin’s theory of evolution. Potential strategies to activate the anti-tumor response of the endogenous immune system combined with CAR-T cell therapy may overcome relapse and maintain long-term remission in the future. With the accumulation of knowledge about the underlying mechanisms of tumor relapse after CAR-T cell therapy, better treatment approaches to induce prolonged RFS in patients are destined to emerge. Though current progress has unraveled only a surface of mystery, by comprehensively studying the cellular interactions and molecular biology from different perspectives and novel angles we will learn much more in the future. 6 Conclusions 1 Studies of relapse after CAR-T cell therapy in B-cell malignancies have revealed deep insights into the underlying mechanisms, and inspired us to come up with various CAR optimization and innovative treatment strategies. As new approaches are tested and implemented, CAR-T cell therapy is destined to bring success to cellular immunotherapy. References Adachi K , Kano Y , Nagai T , et al. , 2018 . IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor . Nat Biotechnol , 36 ( 4 ): 346 - 351 . https://doi.org/10.1038/nbt.4086 https://doi.org/10.1038/nbt.4086 IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor Ajina A , Maher J , 2018 . Strategies to address chimeric antigen receptor tonic signaling . Mol Cancer Ther , 17 ( 9 ): 1795 - 1815 . https://doi.org/10.1158/1535-7163.MCT-17-1097 https://doi.org/10.1158/1535-7163.MCT-17-1097 Strategies to address chimeric antigen receptor tonic signaling Alabanza L , Pegues M , Geldres C , et al. , 2017 . Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains . Mol Ther , 25 ( 11 ): 2452 - 2465 . https://doi.org/10.1016/j.ymthe.2017.07.013 https://doi.org/10.1016/j.ymthe.2017.07.013 Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains Ancos-Pintado R , Bragado-García I , Morales ML , et al. , 2022 . High-throughput CRISPR screening in hematological neoplasms . Cancers (Basel) , 14 ( 15 ): 3612 . https://doi.org/10.3390/cancers14153612 https://doi.org/10.3390/cancers14153612 High-throughput CRISPR screening in hematological neoplasms Artyomov MN , van den Bossche J , 2020 . Immunometabolism in the single-cell era . Cell Metab , 32 ( 5 ): 710 - 725 . https://doi.org/10.1016/j.cmet.2020.09.013 https://doi.org/10.1016/j.cmet.2020.09.013 Immunometabolism in the single-cell era Asnani M , Hayer KE , Naqvi AS , et al. , 2020 . Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 . Leukemia , 34 ( 4 ): 1202 - 1207 . https://doi.org/10.1038/s41375-019-0580-z https://doi.org/10.1038/s41375-019-0580-z Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 Bai ZL , Woodhouse S , Zhao ZR , et al. , 2022 . Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL . Sci Adv , 8 ( 23 ): eabj2820 . https://doi.org/10.1126/sciadv.abj2820 https://doi.org/10.1126/sciadv.abj2820 Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL Baird JH , Frank MJ , Craig J , et al. , 2021 . CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma . Blood , 137 ( 17 ): 2321 - 2325 . https://doi.org/10.1182/blood.2020009432 https://doi.org/10.1182/blood.2020009432 CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma Bao C , Gao QL , Li LL , et al. , 2021 . The application of nanobody in CAR-T therapy . Biomolecules , 11 ( 2 ): 238 . https://doi.org/10.3390/biom11020238 https://doi.org/10.3390/biom11020238 The application of nanobody in CAR-T therapy Biondi M , Cerina B , Tomasoni C , et al. , 2021 . Combining the expression of CD 33 .‍CAR and CXCR4 to increase CAR-CIK cell homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia. Blood , 138 ( S1 ): 2791 - 2791 . https://doi.org/10.1182/blood-2021-152394 https://doi.org/10.1182/blood-2021-152394 Combining the expression of CD Boulch M , Cazaux M , Loe-Mie Y , et al. , 2021 . A cross-talk between CAR T cell subsets and the tumor microenvir onment is essential for sustained cytotoxic activity. Sci Immunol , 6 ( 57 ): eabd4344 . https://doi.org/10.1126/sciimmunol.abd4344 https://doi.org/10.1126/sciimmunol.abd4344 A cross-talk between CAR T cell subsets and the tumor microenvir Calderon H , Mamonkin M , Guedan S , 2020 . Analysis of CAR-mediated tonic signaling . In: Swiech K, Malmegrim KCR, Picanço-Castro V (Eds.), Chimeric Antigen Receptor T Cells . Springer , New York , p. 223 - 236 . https://doi.org/10.1007/978-1-0716-0146-4_17 https://doi.org/10.1007/978-1-0716-0146-4_17 Analysis of CAR-mediated tonic signaling Cancilla D , Rettig MP , Dipersio JF , 2020 . Targeting CXCR4 in AML and ALL . Front Oncol , 10 : 1672 . https://doi.org/10.3389/fonc.2020.01672 https://doi.org/10.3389/fonc.2020.01672 Targeting CXCR4 in AML and ALL Cao Y , Xiao Y , Wang N , et al. , 2021 . CD19/CD22 chimeric antigen receptor T cell cocktail therapy following auto logous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther , 27 ( 11 ): 910.e1 - 910.e11 . https://doi.org/10.1016/j.jtct.2021.08.012 https://doi.org/10.1016/j.jtct.2021.08.012 CD19/CD22 chimeric antigen receptor T cell cocktail therapy following auto Cappell KM , Sherry RM , Yang JC , et al. , 2020 . Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy . J Clin Oncol , 38 ( 32 ): 3805 - 3815 . https://doi.org/10.1200/JCO.20.01467 https://doi.org/10.1200/JCO.20.01467 Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy Chen C , Liu JM , Luo YP , 2020 . MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages . J Zhejiang Univ-Sci B (Biomed & Biotechnol) , 21 ( 1 ): 12 - 28 . https://doi.org/10.1631/jzus.B1900452 https://doi.org/10.1631/jzus.B1900452 MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages Chen GM , Chen CY , Das RK , et al. , 2021 . Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy . Cancer Discov , 11 ( 9 ): 2186 - 2199 . https://doi.org/10.1158/2159-8290.CD-20-1677 https://doi.org/10.1158/2159-8290.CD-20-1677 Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy Chen J , López-Moyado IF , Seo H , et al. , 2019 . NR4A transcription factors limit CAR T cell function in solid tumours . Nature , 567 ( 7749 ): 530 - 534 . https://doi.org/10.1038/s41586-019-0985-x https://doi.org/10.1038/s41586-019-0985-x NR4A transcription factors limit CAR T cell function in solid tumours Chen PH , Lipschitz M , Weirather JL , et al. , 2020 . Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy . JCI Insight , 5 ( 12 ): e134612 https://doi.org/10.1172/jci.insight.134612 https://doi.org/10.1172/jci.insight.134612 Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy Chen YH , Sun C , Landoni E , et al. , 2019 . Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15 . Clin Cancer Res , 25 ( 9 ): 2915 - 2924 . https://doi.org/10.1158/1078-0432.CCR-18-1811 https://doi.org/10.1158/1078-0432.CCR-18-1811 Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15 Chong EA , Melenhorst JJ , Lacey SF , et al. , 2017 . PD-1 blockade modulates chimeric antigen receptor (CAR)‍-modified T cells: refueling the CAR . Blood , 129 ( 8 ): 1039 - 1041 . https://doi.org/10.1182/blood-2016-09-738245 https://doi.org/10.1182/blood-2016-09-738245 PD-1 blockade modulates chimeric antigen receptor (CAR)‍-modified T cells: refueling the CAR Colmone A , Amorim M , Pontier AL , et al. , 2008 . Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells . Science , 322 ( 5909 ): 1861 - 1865 . https://doi.org/10.1126/science.1164390 https://doi.org/10.1126/science.1164390 Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells Dai HR , Wu ZQ , Jia HJ , et al. , 2020 . Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia . J Hematol Oncol , 13 : 30 . https://doi.org/10.1186/s13045-020-00856-8 https://doi.org/10.1186/s13045-020-00856-8 Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia Davenport AJ , Cross RS , Watson KA , et al. , 2018 . Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity . Proc Natl Acad Sci USA , 115 ( 9 ): E2068 - E2076 . https://doi.org/10.1073/pnas.1716266115 https://doi.org/10.1073/pnas.1716266115 Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity da Vià MC , Dietrich O , Truger M , et al. , 2021 . Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma . Nat Med , 27 ( 4 ): 616 - 619 . https://doi.org/10.1038/s41591-021-01245-5 https://doi.org/10.1038/s41591-021-01245-5 Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Deng Q , Han GC , Puebla-Osorio N , et al. , 2020 . Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas . Nat Med , 26 ( 12 ): 1878 - 1887 . https://doi.org/10.1038/s41591-020-1061-7 https://doi.org/10.1038/s41591-020-1061-7 Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Enblad G , Karlsson H , Gammelgård G , et al. , 2018 . A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia . Clin Cancer Res , 24 ( 24 ): 6185 - 6194 . https://doi.org/10.1158/1078-0432.CCR-18-0426 https://doi.org/10.1158/1078-0432.CCR-18-0426 A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia Evans AG , Rothberg PG , Burack WR , et al. , 2015 . Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells . Br J Haematol , 171 ( 2 ): 205 - 209 . https://doi.org/10.1111/bjh.13562 https://doi.org/10.1111/bjh.13562 Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells Fan TWM , Bandura LL , Higashi RM , et al. , 2005 . Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells . Metabolomics , 1 ( 4 ): 325 - 339 . https://doi.org/10.1007/s11306-005-0012-0 https://doi.org/10.1007/s11306-005-0012-0 Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells Fan TWM , Lane AN , Higashi RM , 2016 . Stable isotope resolved metabolomics studies in ex vivo tissue slices . Bio Protoc , 6 ( 3 ): e1730 . https://doi.org/10.21769/bioprotoc.1730 https://doi.org/10.21769/bioprotoc.1730 Stable isotope resolved metabolomics studies in ex vivo tissue slices Fischer J , Paret C , el Malki K , et al. , 2017 . CD19 isoforms enabling resistance to CART-19 immunotherapy are ex CD19 isoforms enabling resistance to CART-19 immunotherapy are ex pressed in B-ALL patients at initial diagnosis . J Immunother , 40 ( 5 ): 187 - 195 . https://doi.org/10.1097/CJI.0000000000000169 https://doi.org/10.1097/CJI.0000000000000169 pressed in B-ALL patients at initial diagnosis Fraietta JA , Lacey SF , Orlando EJ , et al. , 2018a . Determin ants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med , 24 ( 5 ): 563 - 571 . https://doi.org/10.1038/s41591-018-0010-1 https://doi.org/10.1038/s41591-018-0010-1 Determin Fraietta JA , Nobles CL , Sammons MA , et al. , 2018b . Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells . Nature , 558 ( 7709 ): 307 - 312 . https://doi.org/10.1038/s41586-018-0178-z https://doi.org/10.1038/s41586-018-0178-z Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Frank MJ , Hossain NM , Bukhari A , et al. , 2021 . Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial . J Clin Oncol , 39 ( 27 ): 3034 - 3043 . https://doi.org/10.1200/JCO.21.00377 https://doi.org/10.1200/JCO.21.00377 Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial Fry TJ , Shah NN , Orentas RJ , et al. , 2018 . CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy . Nat Med , 24 ( 1 ): 20 - 28 . https://doi.org/10.1038/nm.4441 https://doi.org/10.1038/nm.4441 CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Fultang L , Booth S , Yogev O , et al. , 2020 . Metabolic engin Metabolic engin eering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity . Blood , 136 ( 10 ): 1155 - 1160 . https://doi.org/10.1182/blood.2019004500 https://doi.org/10.1182/blood.2019004500 eering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity Gardner R , Wu D , Cherian S , et al. , 2016 . Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL -rearranged B-ALL from CD19 CAR-T-cell therapy . Blood , 127 ( 20 ): 2406 - 2410 . https://doi.org/10.1182/blood-2015-08-665547 https://doi.org/10.1182/blood-2015-08-665547 Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy Gaudichon J , Jakobczyk H , Debaize L , et al. , 2019 . Mech anisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev , 36 : 40 - 56 . https://doi.org/10.1016/j.blre.2019.04.003 https://doi.org/10.1016/j.blre.2019.04.003 Mech Gennert DG , Lynn RC , Granja JM , et al. , 2021 . Dynamic chroma Dynamic chroma tin regulatory landscape of human CAR T cell exhaustion . Proc Natl Acad Sci USA , 118 ( 30 ): e2104758118 . https://doi.org/10.1073/pnas.2104758118 https://doi.org/10.1073/pnas.2104758118 tin regulatory landscape of human CAR T cell exhaustion Ghoneim HE , Fan YP , Moustaki A , et al. , 2017 . De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation . Cell , 170 ( 1 ): 142 - 157.e19 . https://doi.org/10.1016/j.cell.2017.06.007 https://doi.org/10.1016/j.cell.2017.06.007 De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation Grupp SA , Kalos M , Barrett D , et al. , 2013 . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia . N Engl J Med , 368 ( 16 ): 1509 - 1518 . https://doi.org/10.1056/NEJMoa1215134 https://doi.org/10.1056/NEJMoa1215134 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia Guedan S , Posey AD , Shaw C , et al. , 2018 . Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation . JCI Insight , 3 ( 1 ): e96976 . https://doi.org/10.1172/jci.insight.96976 https://doi.org/10.1172/jci.insight.96976 Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation Guerrouahen BS , Sidahmed H , al Sulaiti A , et al. , 2019 . Enhancing mesenchymal stromal cell immunomodulation for treating conditions influenced by the immune system . Stem Cells Int , 2019 : 7219297 . https://doi.org/10.1155/2019/7219297 https://doi.org/10.1155/2019/7219297 Enhancing mesenchymal stromal cell immunomodulation for treating conditions influenced by the immune system Hamieh M , Dobrin A , Cabriolu A , et al. , 2019 . CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape . Nature , 568 ( 7750 ): 112 - 116 . https://doi.org/10.1038/s41586-019-1054-1 https://doi.org/10.1038/s41586-019-1054-1 CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape Hanahan D , 2022 . Hallmarks of cancer: new dimensions . Cancer Discov , 12 ( 1 ): 31 - 46 . https://doi.org/10.1158/2159-8290.CD-21-1059 https://doi.org/10.1158/2159-8290.CD-21-1059 Hallmarks of cancer: new dimensions Harris DT , Hager MV , Smith SN , et al. , 2018 . Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains . J Immunol , 200 ( 3 ): 1088 - 1100 . https://doi.org/10.4049/jimmunol.1700236 https://doi.org/10.4049/jimmunol.1700236 Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains Hong MH , Clubb JD , Chen YY , 2020 . Engineering CAR-T cells for next-generation cancer therapy . Cancer Cell , 38 ( 4 ): 473 - 488 . https://doi.org/10.1016/j.ccell.2020.07.005 https://doi.org/10.1016/j.ccell.2020.07.005 Engineering CAR-T cells for next-generation cancer therapy Hu TY , Murdaugh R , Nakada D , 2017 . Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia . Front Oncol , 7 : 268 . https://doi.org/10.3389/fonc.2017.00268 https://doi.org/10.3389/fonc.2017.00268 Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia Hu WH , Zi ZG , Jin YL , et al. , 2019 . CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions . Cancer Immunol Immunother , 68 ( 3 ): 365 - 377 . https://doi.org/10.1007/s00262-018-2281-2 https://doi.org/10.1007/s00262-018-2281-2 CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions Hu Y , Zhou Y , Zhang M , et al. , 2021 . CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia . Clin Cancer Res , 27 ( 10 ): 2764 - 2772 . https://doi.org/10.1158/1078-0432.CCR-20-3863 https://doi.org/10.1158/1078-0432.CCR-20-3863 CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia Huang H , Wu HW , Hu YX , 2020 . Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma . J Zhejiang Univ-Sci B (Biomed & Biotechnol) , 21 ( 1 ): 29 - 41 . https://doi.org/10.1631/jzus.B1900351 https://doi.org/10.1631/jzus.B1900351 Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma Hudecek M , Sommermeyer D , Kosasih PL , et al. , 2015 . The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity . Cancer Immunol Res , 3 ( 2 ): 125 - 135 . https://doi.org/10.1158/2326-6066.CIR-14-0127 https://doi.org/10.1158/2326-6066.CIR-14-0127 The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity Jacobson C , Locke FL , Ghobadi A , et al. , 2021 . Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL) . Blood , 138 ( S1 ): 1764 - 1764 . https://doi.org/10.1182/blood-2021-148078 https://doi.org/10.1182/blood-2021-148078 Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL) Jacoby E , Nguyen SM , Fountaine TJ , et al. , 2016 . CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity . Nat Commun , 7 : 12320 . https://doi.org/10.1038/ncomms12320 https://doi.org/10.1038/ncomms12320 CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity Jain MD , Zhao H , Wang XF , et al. , 2021 . Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma . Blood , 137 ( 19 ): 2621 - 2633 . https://doi.org/10.1182/blood.2020007445 https://doi.org/10.1182/blood.2020007445 Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma Jing XM , Yang FM , Shao CC , et al. , 2019 . Role of hypoxia in cancer therapy by regulating the tumor microenvironment . Mol Cancer , 18 : 157 . https://doi.org/10.1186/s12943-019-1089-9 https://doi.org/10.1186/s12943-019-1089-9 Role of hypoxia in cancer therapy by regulating the tumor microenvironment John S , Pulsipher MA , Moskop A , et al. , 2021 . Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the center for international blood and marrow transplant research (CIBMTR) registry . Blood , 138 ( S1 ): 428 . https://doi.org/10.1182/blood-2021-146393 https://doi.org/10.1182/blood-2021-146393 Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the center for international blood and marrow transplant research (CIBMTR) registry Kadomoto S , Izumi K , Mizokami A , 2021 . Macrophage polarity and disease control . Int J Mol Sci , 23 ( 1 ): 144 . https://doi.org/10.3390/ijms23010144 https://doi.org/10.3390/ijms23010144 Macrophage polarity and disease control Kailayangiri S , Altvater B , Wiebel M , et al. , 2020 . Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers . Cancers (Basel) , 12 ( 5 ): 1075 . https://doi.org/10.3390/cancers12051075 https://doi.org/10.3390/cancers12051075 Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers Khan O , Giles JR , Mcdonald S , et al. , 2019 . TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion . Nature , 571 ( 7764 ): 211 - 218 . https://doi.org/10.1038/s41586-019-1325-x https://doi.org/10.1038/s41586-019-1325-x TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion Kong WM , Dimitri A , Wang WL , et al. , 2021 . BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia . J Clin Invest , 131 ( 16 ): e145459 . https://doi.org/10.1172/JCI145459 https://doi.org/10.1172/JCI145459 BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia Kumar V , Patel SM , Tcyganov E , et al. , 2016 . The nature of myeloid-derived suppressor cells in the tumor microenvir onment. Trends Immunol , 37 ( 3 ): 208 - 220 . https://doi.org/10.1016/j.it.2016.01.004 https://doi.org/10.1016/j.it.2016.01.004 The nature of myeloid-derived suppressor cells in the tumor microenvir Langier S , Sade K , Kivity S , 2010 . Regulatory T cells: the suppressor arm of the immune system . Autoimmun Rev , 10 ( 2 ): 112 - 115 . https://doi.org/10.1016/j.autrev.2010.08.013 https://doi.org/10.1016/j.autrev.2010.08.013 Regulatory T cells: the suppressor arm of the immune system Larson RC , Maus MV , 2021 . Recent advances and discoveries in the mechanisms and functions of CAR T cells . Nat Rev Cancer , 21 ( 3 ): 145 - 161 . https://doi.org/10.1038/s41568-020-00323-z https://doi.org/10.1038/s41568-020-00323-z Recent advances and discoveries in the mechanisms and functions of CAR T cells Li N , Hua JL , 2017 . Interactions between mesenchymal stem cells and the immune system . Cell Mol Life Sci , 74 ( 13 ): 2345 - 2360 . https://doi.org/10.1007/s00018-017-2473-5 https://doi.org/10.1007/s00018-017-2473-5 Interactions between mesenchymal stem cells and the immune system Li S , Siriwon N , Zhang XY , et al. , 2017 . Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors . Clin Cancer Res , 23 ( 22 ): 6982 - 6992 . https://doi.org/10.1158/1078-0432.CCR-17-0867 https://doi.org/10.1158/1078-0432.CCR-17-0867 Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors Li YR , Yu YQ , Kramer A , et al. , 2022 . An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy . Cells , 11 ( 9 ): 1583 . https://doi.org/10.3390/cells11091583 https://doi.org/10.3390/cells11091583 An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy Lindo L , Wilkinson LH , Hay KA , 2021 . Befriending the hostile tumor microenvironment in CAR T-cell therapy . Front Immunol , 11 : 618387 . https://doi.org/10.3389/fimmu.2020.618387 https://doi.org/10.3389/fimmu.2020.618387 Befriending the hostile tumor microenvironment in CAR T-cell therapy Long AH , Haso WM , Shern JF , et al. , 2015 . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors . Nat Med , 21 ( 6 ): 581 - 590 . https://doi.org/10.1038/nm.3838 https://doi.org/10.1038/nm.3838 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Lynn RC , Weber EW , Sotillo E , et al. , 2019 . c-Jun overexpression in CAR T cells induces exhaustion resistance . Nature , 576 ( 7786 ): 293 - 300 . https://doi.org/10.1038/s41586-019-1805-z https://doi.org/10.1038/s41586-019-1805-z c-Jun overexpression in CAR T cells induces exhaustion resistance Macian F , 2005 . NFAT proteins: key regulators of T-cell development and function . Nat Rev Immunol , 5 ( 6 ): 472 - 484 . https://doi.org/10.1038/nri1632 https://doi.org/10.1038/nri1632 NFAT proteins: key regulators of T-cell development and function Majzner RG , Mackall CL , 2018 . Tumor antigen escape from CAR T-cell therapy . Cancer Discov , 8 ( 10 ): 1219 - 1226 . https://doi.org/10.1158/2159-8290.CD-18-0442 https://doi.org/10.1158/2159-8290.CD-18-0442 Tumor antigen escape from CAR T-cell therapy Maus MV , Haas AR , Beatty GL , et al. , 2013 . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans . Cancer Immunol Res , 1 ( 1 ): 26 - 31 . https://doi.org/10.1158/2326-6066.CIR-13-0006 https://doi.org/10.1158/2326-6066.CIR-13-0006 T cells expressing chimeric antigen receptors can cause anaphylaxis in humans Mcgranahan N , Swanton C , 2017 . Clonal heterogeneity and tumor evolution: past, present, and the future . Cell , 168 ( 4 ): 613 - 628 . https://doi.org/10.1016/j.cell.2017.01.018 https://doi.org/10.1016/j.cell.2017.01.018 Clonal heterogeneity and tumor evolution: past, present, and the future Melenhorst JJ , Chen GM , Wang M , et al. , 2022 . Decade-long leukaemia remissions with persistence of CD4 + CAR T cells . Nature , 602 ( 7897 ): 503 - 509 . https://doi.org/10.1038/s41586-021-04390-6 https://doi.org/10.1038/s41586-021-04390-6 Decade-long leukaemia remissions with persistence of CD4+ CAR T cells Miao LL , Zhang ZC , Ren ZJ , et al. , 2021 . Reactions related to CAR-T cell therapy . Front Immunol , 12 : 663201 . https://doi.org/10.3389/fimmu.2021.663201 https://doi.org/10.3389/fimmu.2021.663201 Reactions related to CAR-T cell therapy Muñoz L , Nomdedéu JF , López O , et al. , 2001 . Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies . Haematologica , 86 ( 12 ): 1261 - 1269 . Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies Orlando EJ , Han X , Tribouley C , et al. , 2018 . Genetic mech anisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med , 24 ( 10 ): 1504 - 1506 . https://doi.org/10.1038/s41591-018-0146-z https://doi.org/10.1038/s41591-018-0146-z Genetic mech Pauken KE , Sammons MA , Odorizzi PM , et al. , 2016 . Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade . Science , 354 ( 6316 ): 1160 - 1165 . https://doi.org/10.1126/science.aaf2807 https://doi.org/10.1126/science.aaf2807 Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade Peled A , Klein S , Beider K , et al. , 2018 . Role of CXCL12 and CXCR4 in the pathogenesis of hematological malig nancies. Cytokine , 109 : 11 - 16 . https://doi.org/10.1016/j.cyto.2018.02.020 https://doi.org/10.1016/j.cyto.2018.02.020 Role of CXCL12 and CXCR4 in the pathogenesis of hematological malig Pinho S , Frenette PS , 2019 . Haematopoietic stem cell activity and interactions with the niche . Nat Rev Mol Cell Biol , 20 ( 5 ): 303 - 320 . https://doi.org/10.1038/s41580-019-0103-9 https://doi.org/10.1038/s41580-019-0103-9 Haematopoietic stem cell activity and interactions with the niche Prasetyanti PR , Medema JP , 2017 . Intra-tumor heterogeneity from a cancer stem cell perspective . Mol Cancer , 16 : 41 . https://doi.org/10.1186/s12943-017-0600-4 https://doi.org/10.1186/s12943-017-0600-4 Intra-tumor heterogeneity from a cancer stem cell perspective Prinzing B , Zebley CC , Petersen CT , et al. , 2021 . Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity . Sci Transl Med , 13 ( 620 ): eabh0272 . https://doi.org/10.1126/scitranslmed.abh0272 https://doi.org/10.1126/scitranslmed.abh0272 Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity Qi YK , Zhao MF , Hu YX , et al. , 2022 . Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL . Blood , 139 ( 23 ): 3376 - 3386 . https://doi.org/10.1182/blood.2021013733 https://doi.org/10.1182/blood.2021013733 Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL Rafei H , Daher M , Rezvani K , 2021 . Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity . Br J Haematol , 193 ( 2 ):‍ 216 - 230 . https://doi.org/10.1111/bjh.17186 https://doi.org/10.1111/bjh.17186 Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity Rafiq S , Yeku OO , Jackson HJ , et al. , 2018 . Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo . Nat Biotechnol , 36 ( 9 ): 847 - 856 . https://doi.org/10.1038/nbt.4195 https://doi.org/10.1038/nbt.4195 Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo Ramakrishna S , Highfill SL , Walsh Z , et al. , 2019 . Modulation of target antigen density improves CAR T-cell functionality and persistence . Clin Cancer Res , 25 ( 17 ): 5329 - 5341 . https://doi.org/10.1158/1078-0432.CCR-18-3784 https://doi.org/10.1158/1078-0432.CCR-18-3784 Modulation of target antigen density improves CAR T-cell functionality and persistence Ramos CA , Grover NS , Beaven AW , et al. , 2020 . Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma . J Clin Oncol , 38 ( 32 ): 3794 - 3804 . https://doi.org/10.1200/JCO.20.01342 https://doi.org/10.1200/JCO.20.01342 Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma Regmi S , Pathak S , Kim JO , et al. , 2019 . Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives . Eur J Cell Biol , 98 ( 5-8 ): 151041 . https://doi.org/10.1016/j.ejcb.2019.04.002 https://doi.org/10.1016/j.ejcb.2019.04.002 Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives Ren XW , Zhang L , Zhang YY , et al. , 2021 . Insights gained from single-cell analysis of immune cells in the tumor microenvironment . Annu Rev Immunol , 39 : 583 - 609 . https://doi.org/10.1146/annurev-immunol-110519-071134 https://doi.org/10.1146/annurev-immunol-110519-071134 Insights gained from single-cell analysis of immune cells in the tumor microenvironment Roselli E , Faramand R , Davila ML , 2021 . Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes . J Clin Invest , 131 ( 2 ): e142030 . https://doi.org/10.1172/JCI142030 https://doi.org/10.1172/JCI142030 Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes Ruella M , Barrett DM , Kenderian SS , et al. , 2016 . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies . J Clin Invest , 126 ( 10 ): 3814 - 3826 . https://doi.org/10.1172/JCI87366 https://doi.org/10.1172/JCI87366 Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies Ruella M , Xu J , Barrett DM , et al. , 2018 . Induction of resist ance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med , 24 ( 10 ): 1499 - 1503 . https://doi.org/10.1038/s41591-018-0201-9 https://doi.org/10.1038/s41591-018-0201-9 Induction of resist Sadeqi Nezhad M , Abdollahpour-Alitappeh M , Rezaei B , et al. , 2021 . Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products . Pharm Res , 38 ( 6 ): 931 - 945 . https://doi.org/10.1007/s11095-021-03067-z https://doi.org/10.1007/s11095-021-03067-z Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products Sakaguchi S , Ono M , Setoguchi R , et al. , 2006 . Foxp3 + CD 25 +CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev , 212 ( 1 ): 8 - 27 . https://doi.org/10.1111/j.0105-2896.2006.00427.x https://doi.org/10.1111/j.0105-2896.2006.00427.x Foxp3+CD Salter AI , Rajan A , Kennedy JJ , et al. , 2021 . Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function . Sci Signal , 14 ( 697 ): eabe2606 . https://doi.org/10.1126/scisignal.abe2606 https://doi.org/10.1126/scisignal.abe2606 Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function Savoldo B , Ramos CA , Liu EL , et al. , 2011 . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients . J Clin Invest , 121 ( 5 ): 1822 - 1826 . https://doi.org/10.1172/JCI46110 https://doi.org/10.1172/JCI46110 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients Scarfò I , Ormhøj M , Frigault MJ , et al. , 2018 . Anti-CD37 chime ric antigen receptor T cells are active against B- and T-cell lymphomas. Blood , 132 ( 14 ): 1495 - 1506 . https://doi.org/10.1182/blood-2018-04-842708 https://doi.org/10.1182/blood-2018-04-842708 Anti-CD37 chime Scherer F , Kurtz DM , Newman AM , et al. , 2016 . Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA . Sci Transl Med , 8 ( 364 ): 364ra155 . https://doi.org/10.1126/scitranslmed.aai8545 https://doi.org/10.1126/scitranslmed.aai8545 Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA Schneider D , Xiong Y , Wu DR , et al. , 2017 . A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines . J Immunother Cancer , 5 ( 1 ): 42 . https://doi.org/10.1186/s40425-017-0246-1 https://doi.org/10.1186/s40425-017-0246-1 A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines Sen DR , Kaminski J , Barnitz RA , et al. , 2016 . The epigenetic landscape of T cell exhaustion . Science , 354 ( 6316 ): 1165 - 1169 . https://doi.org/10.1126/science.aae0491 https://doi.org/10.1126/science.aae0491 The epigenetic landscape of T cell exhaustion Seo H , Chen J , González-Avalos E , et al. , 2019 . TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion . Proc Natl Acad Sci USA , 116 ( 25 ): 12410 - 12415 . https://doi.org/10.1073/pnas.1905675116 https://doi.org/10.1073/pnas.1905675116 TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion Shaffer DR , Savoldo B , Yi ZZ , et al. , 2011 . T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies . Blood , 117 ( 16 ): 4304 - 4314 . https://doi.org/10.1182/blood-2010-04-278218 https://doi.org/10.1182/blood-2010-04-278218 T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies Shah NN , Qin HY , Yates B , et al. , 2019 . Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy . Blood Adv , 3 ( 15 ): 2317 - 2322 . https://doi.org/10.1182/bloodadvances.2019000219 https://doi.org/10.1182/bloodadvances.2019000219 Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy Shalabi H , Kraft IL , Wang HW , et al. , 2018 . Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma . Haematologica , 103 ( 5 ): e215 - e218 . https://doi.org/10.3324/haematol.2017.183459 https://doi.org/10.3324/haematol.2017.183459 Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma Shao M , Teng XY , Guo X , et al. , 2022 . Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways . Adv Sci (Weinh) , 9 ( 9 ): 2103508 . https://doi.org/10.1002/advs.202103508 https://doi.org/10.1002/advs.202103508 Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways Si XH , Xiao L , Brown CE , et al. , 2022 . Preclinical evaluation of CAR T cell function: in vitro and in vivo models . Int J Mol Sci , 23 ( 6 ): 3154 . https://doi.org/10.3390/ijms23063154 https://doi.org/10.3390/ijms23063154 Preclinical evaluation of CAR T cell function: in vitro and in vivo models Siddiqi T , Wang XL , Blanchard MS , et al. , 2021 . CD19-directed CAR T-cell therapy for treatment of primary CNS lymph oma. Blood Adv , 5 ( 20 ): 4059 - 4063 . https://doi.org/10.1182/bloodadvances.2020004106 https://doi.org/10.1182/bloodadvances.2020004106 CD19-directed CAR T-cell therapy for treatment of primary CNS lymph Singh N , Lee YG , Shestova O , et al. , 2020 . Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction . Cancer Discov , 10 ( 4 ): 552 - 567 . https://doi.org/10.1158/2159-8290.CD-19-0813 https://doi.org/10.1158/2159-8290.CD-19-0813 Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction Sotillo E , Barrett DM , Black KL , et al. , 2015 . Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy . Cancer Discov , 5 ( 12 ): 1282 - 1295 . https://doi.org/10.1158/2159-8290.CD-15-1020 https://doi.org/10.1158/2159-8290.CD-15-1020 Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy Stepanov AV , Markov OV , Chernikov IV , et al. , 2018 . Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma . Sci Adv , 4 ( 11 ): eaau4580 . https://doi.org/10.1126/sciadv.aau4580 https://doi.org/10.1126/sciadv.aau4580 Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma Sterner RC , Sterner RM , 2021 . CAR-T cell therapy: current limitations and potential strategies . Blood Cancer J , 11 ( 4 ): 69 . https://doi.org/10.1038/s41408-021-00459-7 https://doi.org/10.1038/s41408-021-00459-7 CAR-T cell therapy: current limitations and potential strategies Sun Y , Su YF , Wang YZ , et al. , 2021 . CD19 CAR-T cells with membrane-bound IL-15 for B-cell acute lymphoblastic leukemia after failure of CD19 and CD22 CAR-T cells: case report . Front Immunol , 12 : 728962 . https://doi.org/10.3389/fimmu.2021.728962 https://doi.org/10.3389/fimmu.2021.728962 CD19 CAR-T cells with membrane-bound IL-15 for B-cell acute lymphoblastic leukemia after failure of CD19 and CD22 CAR-T cells: case report Tallen G , Ratei R , Mann G , et al. , 2010 . Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 . J Clin Oncol , 28 ( 14 ): 2339 - 2347 . https://doi.org/10.1200/JCO.2009.25.1983 https://doi.org/10.1200/JCO.2009.25.1983 Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 Tan Y , Pan J , Deng BP , et al. , 2021 . Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL . Cancer Immunol Immunother , 70 ( 7 ): 1979 - 1993 . https://doi.org/10.1007/s00262-020-02829-9 https://doi.org/10.1007/s00262-020-02829-9 Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL Thankamony AP , Subbalakshmi AR , Jolly MK , et al. , 2021 . Lineage plasticity in cancer: the tale of a skin-walker . Cancers (Basel) , 13 ( 14 ): 3602 . https://doi.org/10.3390/cancers13143602 https://doi.org/10.3390/cancers13143602 Lineage plasticity in cancer: the tale of a skin-walker Thoms JAI , Pimanda JE , Heidenreich O , 2021 . To switch or not to switch: PU .‍ 1 expression is the question. Blood , 138 ( 15 ): 1289 - 1291 . https://doi.org/10.1182/blood.2021012112 https://doi.org/10.1182/blood.2021012112 To switch or not to switch: PU Tong C , Zhang Y , Liu Y , et al. , 2020 . Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma . Blood , 136 ( 14 ): 1632 - 1644 . https://doi.org/10.1182/blood.2020005278 https://doi.org/10.1182/blood.2020005278 Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma Tu SF , Zhou X , Guo ZL , et al. , 2019 . CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma . Front Oncol , 9 : 1350 . https://doi.org/10.3389/fonc.2019.01350 https://doi.org/10.3389/fonc.2019.01350 CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma van Bruggen JAC , Martens AWJ , Fraietta JA , et al. , 2019 . Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy . Blood , 134 ( 1 ): 44 - 58 . https://doi.org/10.1182/blood.2018885863 https://doi.org/10.1182/blood.2018885863 Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy Walker AJ , Majzner RG , Zhang L , et al. , 2017 . Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase . Mol Ther , 25 ( 9 ): 2189 - 2201 . https://doi.org/10.1016/j.ymthe.2017.06.008 https://doi.org/10.1016/j.ymthe.2017.06.008 Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase Wang DR , Prager BC , Gimple RC , et al. , 2021 . CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies . Cancer Discov , 11 ( 5 ): 1192 - 1211 . https://doi.org/10.1158/2159-8290.CD-20-1243 https://doi.org/10.1158/2159-8290.CD-20-1243 CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies Wang H , Kaur G , Sankin AI , et al. , 2019 . Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies . J Hematol Oncol , 12 : 59 . https://doi.org/10.1186/s13045-019-0746-1 https://doi.org/10.1186/s13045-019-0746-1 Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies Wang JS , Hu YX , Huang H , 2017 . Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy . J Leukoc Biol , 102 ( 6 ): 1347 - 1356 . https://doi.org/10.1189/jlb.5RU0817-315R https://doi.org/10.1189/jlb.5RU0817-315R Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy Wang WL , Fasolino M , Cattau B , et al. , 2020 . Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels . Proc Natl Acad Sci USA , 117 ( 10 ): 5442 - 5452 . https://doi.org/10.1073/pnas.1919259117 https://doi.org/10.1073/pnas.1919259117 Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels Wang Y , Tong C , Dai HR , et al. , 2021 . Low-dose decitabine priming endows CAR T cells with enhanced and persist ent antitumour potential via epigenetic reprogramming. Nat Commun , 12 : 409 . https://doi.org/10.1038/s41467-020-20696-x https://doi.org/10.1038/s41467-020-20696-x Low-dose decitabine priming endows CAR T cells with enhanced and persist Weber EW , Parker KR , Sotillo E , et al. , 2021 . Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling . Science , 372 ( 6537 ): eaba1786 . https://doi.org/10.1126/science.aba1786 https://doi.org/10.1126/science.aba1786 Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling Webster B , Xiong Y , Hu PR , et al. , 2021 . Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19 + Raji lymphoma in preclinical models . Mol Ther , 29 ( 9 ): 2691 - 2706 . https://doi.org/10.1016/j.ymthe.2021.05.006 https://doi.org/10.1016/j.ymthe.2021.05.006 Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models Williams MTS , Yousafzai YM , Elder A , et al. , 2016 . The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts . Blood , 127 ( 16 ): 1998 - 2006 . https://doi.org/10.1182/blood-2015-08-665034 https://doi.org/10.1182/blood-2015-08-665034 The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts Wilson WR , Hay MP , 2011 . Targeting hypoxia in cancer therapy . Nat Rev Cancer , 11 ( 6 ): 393 - 410 . https://doi.org/10.1038/nrc3064 https://doi.org/10.1038/nrc3064 Targeting hypoxia in cancer therapy Xia LZ , Oyang L , Lin JG , et al. , 2021 . The cancer metabolic reprogramming and immune response . Mol Cancer , 20 : 28 . https://doi.org/10.1186/s12943-021-01316-8 https://doi.org/10.1186/s12943-021-01316-8 The cancer metabolic reprogramming and immune response Xu XQ , Gnanaprakasam JNR , Sherman J , et al. , 2019 . A metabolism toolbox for CAR T therapy . Front Oncol , 9 : 322 . https://doi.org/10.3389/fonc.2019.00322 https://doi.org/10.3389/fonc.2019.00322 A metabolism toolbox for CAR T therapy Yan LE , Zhang HY , Wada M , et al. , 2020 . Targeting two antigens associated with B-ALL with CD19-CD123 compound CAR T cell therapy . Stem Cell Rev Rep , 16 ( 2 ): 385 - 396 . https://doi.org/10.1007/s12015-019-09948-6 https://doi.org/10.1007/s12015-019-09948-6 Targeting two antigens associated with B-ALL with CD19-CD123 compound CAR T cell therapy Yan N , Wang N , Wang GX , et al. , 2022 . CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation . Cytotherapy , 24 ( 8 ): 841 - 849 . https://doi.org/10.1016/j.jcyt.2022.01.011 https://doi.org/10.1016/j.jcyt.2022.01.011 CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation Yan X , Chen DY , Wang Y , et al. , 2022 . Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies . Signal Transduct Target Ther , 7 : 98 . https://doi.org/10.1038/s41392-022-00915-1 https://doi.org/10.1038/s41392-022-00915-1 Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies Yan ZX , Li L , Wang W , et al. , 2019 . Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma . Clin Cancer Res , 25 ( 23 ): 6995 - 7003 . https://doi.org/10.1158/1078-0432.CCR-19-0101 https://doi.org/10.1158/1078-0432.CCR-19-0101 Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma Yang X , Yu QX , Xu H , et al. , 2021 . Upregulation of CD22 by chidamide promotes CAR T cells functionality . Sci Rep , 11 ( 1 ): 20637 . https://doi.org/10.1038/s41598-021-00227-4 https://doi.org/10.1038/s41598-021-00227-4 Upregulation of CD22 by chidamide promotes CAR T cells functionality Yang XO , Nurieva R , Martinez GJ , et al. , 2008 . Molecular antagonism and plasticity of regulatory and inflammatory T cell programs . Immunity , 29 : 44 - 56 . https://doi.org/10.1016/j.immuni.2008.05.007 https://doi.org/10.1016/j.immuni.2008.05.007 Molecular antagonism and plasticity of regulatory and inflammatory T cell programs Ying ZT , He T , Wang XP , et al. , 2019 . Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s lymphoma . Mol Ther Oncolytics , 15 : 60 - 68 . https://doi.org/10.1016/j.omto.2019.08.002 https://doi.org/10.1016/j.omto.2019.08.002 Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s lymphoma You LS , Han QM , Zhu L , et al. , 2020 . Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells . Front Immunol , 11 : 1787 . https://doi.org/10.3389/fimmu.2020.01787 https://doi.org/10.3389/fimmu.2020.01787 Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells Yu H , Sotillo E , Harrington C , et al. , 2017 . Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma . Am J Hematol , 92 ( 1 ): E11 - E13 . https://doi.org/10.1002/ajh.24594 https://doi.org/10.1002/ajh.24594 Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma Zah E , Lin MY , Silva-Benedict A , et al. , 2016 . T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells . Cancer Immunol Res , 4 ( 6 ): 498 - 508 . https://doi.org/10.1158/2326-6066.CIR-15-0231 https://doi.org/10.1158/2326-6066.CIR-15-0231 T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells Zanetti SR , Romecin PA , Vinyoles M , et al. , 2020 . Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity . J Immunother Cancer , 8 ( 2 ): e001419 . https://doi.org/10.1136/jitc-2020-001419 https://doi.org/10.1136/jitc-2020-001419 Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity Zebley CC , Brown C , Mi T , et al. , 2021 . CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia . Cell Rep , 37 ( 9 ): 110079 . https://doi.org/10.1016/j.celrep.2021.110079 https://doi.org/10.1016/j.celrep.2021.110079 CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia Zhang L , Tian L , Dai XY , et al. , 2020 . Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions . J Hematol Oncol , 13 : 153 . https://doi.org/10.1186/s13045-020-00983-2 https://doi.org/10.1186/s13045-020-00983-2 Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions Zhang Z , Chen XF , Tian YG , et al. , 2020 . Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy . J Immunother Cancer , 8 ( 2 ): e001150 . https://doi.org/10.1136/jitc-2020-001150 https://doi.org/10.1136/jitc-2020-001150 Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy Zheng WC , Xue QF , Sha XP , et al. , 2021 . Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review . Cancer Biol Ther , 22 ( 10-12 ): 537 - 543 . https://doi.org/10.1080/15384047.2021.1967083 https://doi.org/10.1080/15384047.2021.1967083 Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review Zhou Z , Han Y , Pan HB , et al. , 2021 . Tri-specific CD19×CD20×CD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models . Blood , 138 ( S1 ): 1700 . https://doi.org/10.1182/blood-2021-150650 https://doi.org/10.1182/blood-2021-150650 Tri-specific CD19×CD20×CD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models Zhou ZL , van der Jeught K , Fang YZ , et al. , 2021 . An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity . Nat Biomed Eng , 5 ( 11 ): 1320 - 1335 . https://doi.org/10.1038/s41551-021-00805-x https://doi.org/10.1038/s41551-021-00805-x An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity Tianning GU and Meng ZHU wrote the original manuscript. Tianning GU drafted the figures. Yongxian HU and He HUANG were responsible for conceptualization and manuscript revision. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data. This work was supported by the National Natural Science Foundation of China (No. 81730008). 10.1631/jzus.B2200256 1673-1581（2022）10-0793-19 This work was supported by the National Natural Science Foundation of China (No. 81730008). 2022-04-30 2022-08-10 2022-10-15 2022-12-27 2022-09-19 Copyright © Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2022 2022 浙江大学出版社 Tianning GU, Meng ZHU, He HUANG, and Yongxian HU declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this review. This review does not contain any studies with human or animal subjects performed by any of the authors. Compliance with ethics guidelines 浙江大学学报（英文版）（B辑：生物医学和生物技术） 10 23